Oxford BioMedica appoints John Dawson CEO
This article was originally published in Scrip
Executive Summary
The UK gene therapy company Oxford BioMedicahas appointed John Dawson as permanent chief executive officer; he has served as acting CEO since August 29th. From 1996 to 2007, Mr Dawson held senior management positions in the European operations of Cephalon, including from 2005 as chief financial officer and head of business development Europe.